POSTERS & ABSTRACTS

2018

April 14-18, 2018
Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors. Seitz L, Ashok D, Leleti M, Powers J, Rosen B, Miles D, Sharif E, Jin L, Park A, Young S, Soriano F, Rieger A, Karakunnel J, Walters MJ. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 3769.

View Poster

April 14-18, 2018
Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Walters MJ, Piovesan D, Tan JBL, DiRenzo D, Yin F, Miles D, Leleti M, Park T, Soriano F, Sharif E, Schindler U and Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 5556.

View Poster

April 14-18, 2018
Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody. Tan JBL, Chen C, Chen K, Li G, Li J, Liu J, Singh H, Wang G, Yang B, Zhang K, Zhao X, Zheng Y. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4561.

View Poster

April 14-18, 2018
CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by Immune Checkpoint Inhibitors (ICI). Becker A, Narasappa, N, Yin F, Zhang K, Park T, Kalisiak J, Lawson K, Jeffrey J, Powers JP, Schindler U, Walters, MJ, Tan JBL. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 710.

View Poster

April 14-18, 2018
Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy. Lawson KV, Jin L, Jeffrey J, Kalisiak J, Yin F, Zhang K, Chen A, Swinarski D, Walters MJ, Young S, Schindler U, Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4886.

View Poster

March 23-27, 2018
Adenosinergic Axis Provides an Anchor in Multiple Anti-tumor Combination Strategies. Tan JBL, Becker A, Piovesan D, Yin FF, Soriano F, Leleti M, Jeffrey J, Miles D, Powers JP, Schindler U, Walters MJ. Keystone Symposia on Molecular and Cell Biology: Cancer Immunotherapy: Combinations, Montreal, Canada; Abstract No. 3031.

View Poster

2017

Nov 8-12, 2017
AB928, a dual antagonist of the 
A2aand A2badenosine receptors for the treatment of cancer. Walters MJ, Direnzo D, Tan BLJ, Schindler U, Piovesan D, Ashok D, Park T, Narasappa N, Yin F, Lim WH, Garrido-Shaqfeh S, Jeffrey JL, Debien L, Rosen B, Sharif E, Miles D, Leleti M, & Powers JP. 32nd Annual Meeting of the Society for Immuno-Therapy of Cancer; National Harbor, MD;  Abstract No. P498.

View Poster

Nov 8-12, 2017
Reversal of adenosine-mediated immune suppression by AB421, a potent and selective small-molecule CD73 inhibitor. Tan JBL, Becker A, DiRenzo D, Zhang K, Chen A, Thomas-Tran R, Beatty J, Mandal D, Xu G, Young S, Walters MJ, Schindler U & Powers JPP. 32nd Annual Meeting of the Society for Immuno-Therapy of Cancer; National Harbor, MD; Abstract No. P494.

View Poster

Nov 8-12, 2017
Characterization of AB928, a dual adenosine A2aR/A2bantagonist that retains potency under conditions of high albumin and high receptor activation. Ashok D, Seitz L, Tan JBL, Park A, Park T, Soriano F, Rosen B, Sharif E, Miles D, Leleti MR, Powers JP, Walters MJ & Young S 32nd Annual Meeting of the Society for Immuno-Therapy of Cancer; National Harbor, MD; Abstract No. P6.

Sept 6-9, 2017
AB928, a potent, dual A2aR/A2bsmall molecule antagonist for the treatment of cancer. Schindler U, Tan JBL, Becker A, Ashok D, DiRenzo Dan, Yin F, Park T, Lim W, Xu G, Powers JP, Leleti MR, Sharif E, Miles D, Rosen B, Young S, Lim WS, Garrido-Shaqfeh S, & Walters MJ. CRI-CIMT-EATI-AACR Intl Cancer Immunotherapy Conf.; Frankfurt (Germany); Abstract No. B135”.

April 1-5, 2017
Characterization of the potent and selective A2antagonist AB928 for the treatment of cancer. Walters MJ, Tan JBL, Becker A, Yi F, Park T, Leleti MR, Rosen B, Sharif E, Debien L, Young S, Lim WS, Garrido-Shaqfeh S, Jaen JC and Powers JP. Annual Meeting of the American Association of Cancer Research; Washington, DC; Abstract No. 4572.

View Poster

April 1-5, 2017
Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-cancer targets in the ATP/adenosine signaling pathway. Schindler U, Tan J, Walters M, Becker A, Yin F, Chen A, Chen Y, Powers JP, Lim WH, Young S, Jaen JC.  Annual Meeting of the American Association of Cancer Research; Washington, DC; Abstract No. 2640.

View Poster

April 1-5, 2017
Small-molecule inhibitors of CD73, CD39 and A2aR: Three anti-cancer targets in the ATP/adenosine signaling pathway. Schindler U, Tan J, Walters M, Becker A, Yin F, Chen A, Chen Y, Powers JP, Lim WH, Young S, Jaen JC. Annual Meeting of the American Association of Cancer Research; Washington, DC; Abstract No. 2640.

March 19-23, 2017
Characterization of AB154, a humanized α-TIGIT antibody for the treatment of cancer. Tso JY, Tsurushita N, Duramad O, Tan BLJ, Zhao S, Walters MJ. Keystone Symposium on Cancer Immunology, Whistler, BC (Canada); Abstract No. 3082.

March 19-23, 2017
Characterization of AB928, an A2antagonist for the treatment of cancer. Tan JBL, Walters MJ, Becker A, Yi F, Park T, Leleti MR, Miles D, Jeffery J, Thomas-Tran R, Young S, Lim WS, Garrido-Shaqfeh S, Jaen JC, Powers JP. Keystone Symposium on Cancer Immunology, Whistler, BC (Canada); Abstract No. 3055.

March 22-22, 2017
Small-molecule inhibitors of ecto-nucleotidase CD73 result in strong activation of human and mouse CD8+ T cells in the presence of exogenous AMP, affect tumor growth and positively affect anti-tumor immunity in mouse syngeneic tumor models. Becker A, Tan JBL, Chen A, Lawson K, Lindsey E, Powers JP, Walters M, Schindler U, Young S, Jaen JC. 4th Immunotherapy of Cancer Conference (ITOC-4), Prague (Czech Rep.); Oral Presentation.

2016

Nov 29 – Dec 2, 2016
Novel small-molecule inhibitors of ecto-nucleotidase CD73: Activation of human CD8+ T cells and effects on tumor growth and immune parameters in experimental tumor models. Schindler U, Chen A, Leleti M, Debien L, Lawson K, Rosen B, Powers JP, Tan JBL, Sexton H, Park T, Young S, and Jaen JC. EORTC-NCI-AACR Molecular Targets & Cancer Therapeutics Symposium; Munich, Abstract # 292.

Nov 9-13, 2016
Selective small molecule inhibitors of CD73 promote human CD8+ T cell activation and positively impact tumor growth and immune parameters in experimental tumor models. Powers JP, Becker A, Chen A, Leleti M, Newcomb E, Sexton H, Schindler U, Tan JBL, Young S, and Jaen JC. 31st Annual Meeting of the Society for Immuno-Therapy of Cancer; National Harbor, MD.

Nov 9-13, 2016
Use of experimental tumor models to characterize the effects of CD73 inhibitors on tumor biology and immune infiltrate. Jaen JC, Tan JBL, Chen A, Chen Y, Park T, Powers JP, Sexton H, Xu G, Young S and Schindler U. 31st Annual Meeting of the Society for Immuno-Therapy of Cancer; National Harbor, MD.

Oct 20-23, 2016
Small-molecule inhibitors of ecto-nucleotidase CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumor models. Tan JBL, Chen A, Leleti M, Becker, A, Debien L, Kalisiak J, Powers JP, Schindler U, Tan JBL, Young S, and Jaen JC. Tumor Immunology and Immunotherapy Symposium; Boston MA.

Sept 25-28, 2016
Small-molecule inhibitors of ecto-nucleotidase CD73 promote activation of human CD8+ T cells and have profound effects on tumor growth and immune parameters in experimental tumor models. Jaen JC, Chen A, Chiou SH, Leleti M, Lindsey E, Kalisiak J, Powers JP, Schindler U, Tan JBL, and Young S. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference; New York, Oral Presentation & Poster No. B039.